Antiviral Therapy for Herpes Simplex Virus Infections

Treatment Recommendations

For mild to moderate mucocutaneous infections in pediatric patients, oral acyclovir is recommended at 20 mg/kg/dose (maximum 400 mg/dose) three times daily for 5-14 days, as suggested by the Centers for Disease Control and Prevention (CDC) 1
For CNS or disseminated disease, the recommended treatment is 20 mg/kg IV every 8 hours for 21 days, according to the CDC 1
For skin, eye, or mouth disease, the CDC recommends 20 mg/kg IV every 8 hours for 14 days 1
The following dosages are recommended for various conditions:

Condition	Dosage
Mild gingivostomatitis	20 mg/kg (max 400 mg) 3 times a day for 5-10 days
Moderate or severe gingivostomatitis	5-10 mg/kg 3 times a day IV, then switch to oral
Genital herpes	20 mg/kg (max 400 mg) 3 times a day for 5-14 days
Chickenpox (mild disease)	20 mg/kg/dose (max 800 mg/dose) 4 times daily for 5-7 days

Valacyclovir may be used as a first-line treatment at a dosage of 1 g twice daily for 7-10 days, according to the guidelines 2
Famciclovir is recommended as an alternative treatment at a dosage of 250 mg three times daily for 7-10 days, according to the guidelines 2
For patients with HSV detectable in the cerebrospinal fluid (CSF) after 2-3 weeks of IV therapy, Valacyclovir 2 g three times daily is recommended due to its superior bioavailability compared to oral acyclovir, as suggested by the American NIAID Collaborative Antiviral Study Group 3

The treatment duration for mucocutaneous infections is 5-14 days, as suggested by the CDC 1
For CNS involvement, the recommended treatment duration is 21 days, according to the CDC 1
Clinical response, renal function, and adverse effects such as nausea, headache, and nephropathy should be monitored, especially with high-dose valacyclovir, as suggested by the American NIAID Collaborative Antiviral Study Group 3
Monitor for potential adverse effects, including gastrointestinal symptoms, headache, and rarely, neutropenia with prolonged use, according to the CDC 1
Maintaining adequate hydration is recommended to reduce the risk of nephropathy, as stated by the MMWR Recommendations and Reports guidelines 4
Renal function should be monitored during treatment, especially with prolonged courses, as recommended by the Journal of Infection guidelines 4

Dose adjustment is necessary for patients with renal impairment, as acyclovir is primarily eliminated by the kidneys, according to the National Kidney Foundation 1
The optimal time to transition from IV to oral therapy is after clinical improvement is evident, lesions begin to regress, and the patient can tolerate oral medications, with confirmation of negative CSF HSV PCR after 14-21 days of IV therapy for HSV encephalitis, as recommended by the American NIAID Collaborative Antiviral Study Group 3
Initial treatment with intravenous acyclovir is recommended for severe cases, followed by transition to oral acyclovir at the same dose once lesions begin to regress, according to the CDC 1

The American Academy of Pediatrics recommends prophylaxis after exposure with 10 mg/kg four times daily for 7 days (if initiated within 7-10 days of exposure) 5
The CDC recommends oral acyclovir in children, which has demonstrated reduction in duration of fever and severity of cutaneous symptoms when initiated within 24 hours of rash onset 6
For recurrent episodes of viral blisters, consider episodic therapy with oral acyclovir at the first sign of prodrome or lesions, and for frequent recurrences (≥6 episodes per year), consider daily suppressive therapy, as recommended by the guidelines 2, 1